Literature DB >> 32535937

Lysophosphatidylserine induces eosinophil extracellular trap formation and degranulation: Implications in severe asthma.

Hye Jeong Kim1, Myeong Seong Sim1, Dong Hyun Lee2, Chun Kim3, Youngwoo Choi2, Hae-Sim Park2, Il Yup Chung1,3.   

Abstract

BACKGROUND: Recent evidence demonstrates that activated eosinophils undergo a distinct form of lytic cell death, accompanied by formation of DNA-based eosinophil extracellular trap (EET) and degranulation, enhancing inflammatory immune responses in asthmatic airways. We previously showed that human blood eosinophils undergo degranulation in response to lysophosphatidylserine (LysoPS), an inflammatory lipid mediator, and strongly express P2Y10, a LysoPS receptor.
METHODS: We evaluated EET, degranulation, and cell death of eosinophils in response to various concentrations of LysoPS. We also compared responsiveness to LysoPS between eosinophils from severe and nonsevere asthmatics.
RESULTS: Extensive EET formation was elicited from a substantial fraction of stimulated eosinophils in response to 50 μmol/L LysoPS. Analyses for LDH and eosinophil-derived neurotoxin release showed that both lytic cell death and degranulation accompanied EET formation in response to LysoPS. Cytological analyses demonstrated that citrullinated histone 3 was present in the extracellular, filamentous DNA structure embedded with eosinophil granules. The LysoPS-induced EET was independent of ROS production and irrelevant to several signaling pathways examined, but dependent on protein arginine deiminase 4. A low concentration of LysoPS (5 μmol/L) did not induce EET or degranulation, but significantly increased platelet-activating factor-induced degranulation. Eosinophils from severe asthmatics exhibited greater degranulation, but not EET formation, in response to LysoPS (50 μmol/L), than those from nonsevere asthmatics, along with great expression of surface P2Y10.
CONCLUSIONS: We identified a novel function of LysoPS, namely induction of EET in association with cytolysis and degranulation. LysoPS-dependent EET or degranulation plays a potential role in eosinophilic inflammation of severe asthma.
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  degranulation; eosinophil; eosinophil extracellular trap; eosinophil-derived neurotoxin; lysophosphatidylserine; severe asthma

Mesh:

Substances:

Year:  2020        PMID: 32535937     DOI: 10.1111/all.14450

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

Review 1.  Extracellular Traps: A Novel Therapeutic Target for Severe Asthma.

Authors:  Youngwoo Choi; Quoc Quang Luu; Hae-Sim Park
Journal:  J Asthma Allergy       Date:  2022-06-14

Review 2.  Extracellular DNA Traps: Origin, Function and Implications for Anti-Cancer Therapies.

Authors:  Medina Mamtimin; Akif Pinarci; Chao Han; Attila Braun; Hans-Joachim Anders; Thomas Gudermann; Elmina Mammadova-Bach
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

Review 3.  Emerging Role of Phospholipase-Derived Cleavage Products in Regulating Eosinophil Activity: Focus on Lysophospholipids, Polyunsaturated Fatty Acids and Eicosanoids.

Authors:  Eva Knuplez; Eva Maria Sturm; Gunther Marsche
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 4.  Neutrophil extracellular traps in fungal infections: A seesaw battle in hosts.

Authors:  Hua Zhong; Ren-Yi Lu; Yan Wang
Journal:  Front Immunol       Date:  2022-09-14       Impact factor: 8.786

Review 5.  How to detect eosinophil ETosis (EETosis) and extracellular traps.

Authors:  Mineyo Fukuchi; Yui Miyabe; Chikako Furutani; Tomoo Saga; Yuki Moritoki; Takechiyo Yamada; Peter F Weller; Shigeharu Ueki
Journal:  Allergol Int       Date:  2020-11-12       Impact factor: 7.478

Review 6.  Current Knowledge on the Biology of Lysophosphatidylserine as an Emerging Bioactive Lipid.

Authors:  Jumpei Omi; Kuniyuki Kano; Junken Aoki
Journal:  Cell Biochem Biophys       Date:  2021-06-15       Impact factor: 2.194

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.